Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-In-Human Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of ML261, an Autologous Anti-DLL3 CAR + CARD11-PIK3R3 Fusion T Cell Therapy, in Participants With Relapsed/Refractory Small Cell Lung Cancer or Select Neuroendocrine Carcinomas

NCT07488923 is registered in ClinicalTrials.gov with Moonlight Bio, Inc as lead sponsor.

NCT NCT07488923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07488923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-In-Human Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of ML261, an Autologous Anti-DLL3 CAR + CARD11-PIK3R3 Fusion T Cell Therapy, in Participants With Relapsed/Refractory Small Cell Lung Cancer or Select Neuroendocrine Carcinomas
Lead sponsor
Moonlight Bio, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
June 23, 2026
Completion date
August 31, 2030
Enrollment
110 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

extrapulmonary neuroendocrine carcinoma (ep-nec), gastroenteropancreatic nec (gep nec), neuroendocrine prostate cancer (nepc), small cell lung cancer (sclc )